ARK Genomic Revolution ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
ARK Genomic Revolution ETF ARKG
Morningstar’s Analysis ARKG
Will ARKG outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 62.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Twist Bioscience Corp | 10.30 | 232M | Healthcare |
10x Genomics Inc Ordinary Shares - Class A | 10.02 | 226M | Healthcare |
Tempus AI Inc Class A common stock | 8.93 | 201M | Healthcare |
CRISPR Therapeutics AG | 5.24 | 118M | Healthcare |
Absci Corp | 5.06 | 114M | Healthcare |
Personalis Inc | 4.88 | 110M | Healthcare |
Guardant Health Inc | 4.61 | 104M | Healthcare |
Natera Inc | 4.53 | 102M | Healthcare |
Illumina Inc | 4.49 | 101M | Healthcare |
CareDx Inc | 4.34 | 98M | Healthcare |